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Microcytic anemia secondary to intraperitoneal aluminum in normal
and uremic rats. Dialysis patients exposed to high aluminum (Al) di-
alysate develop a microcytic anemia which is reversed by deionization
(DI) of the dialysate. Because DI removes substances in addition to Al
which are known to cause anemia, these experiments were undertaken
to determine if Al causes anemia and if the anemia of uremia can be
enhanced by Al. Four groups of rats were studied: sham control (A) N
= 6; uremic control (B) N = 6; Al-loaded non-uremic (C) N 7; and
Al-loaded uremic (D) N = 5. Aluminum treatment was I mg Al intra-
peritoneally daily for 6 weeks. Uremic rats (B+D) were 1 5/6 nephrec-
tomized; non-uremic (A C) were sham-operated. Blood samples (200
d) were obtained prior to (C1) and weekly during treatment (T1 to T6)
and analyzed by Coulter Counter. No significant difference in hemo-
globin (Hb), hematocrit (Hct), or mean cell volume (MCV) was noted
at C1. At T3, MCV of Al-treated rats (C+D) was significantly less than
sham control (A) (55.1 0.5 and 53.0 0.8 vs. 60.8 1.5 p, P <
0.05). At T6, MCV, Hb, and Hct of Al-loaded uremic rats (D) (49
0.5 s3; 11.8 0.5 g/dl; 25.1 2%) were significantly less than both A
(58.6 1.3 s3; 16.1 0.4 g/dl; 44.8 0.3%) and B (58.7 1.4 i;
13.8 0.4 g/dl; 33.6 0.5%) (P < 0.05) and MCV, Hb, and Hct of
Al-loaded non-uremic rats (C) (51.7 1.7 3; 12.6 0.3 g/dl; 29.4
1.5%) was significantly less than A (P < 0.05). We conclude that: (1)
Anemia is a specific toxic manifestation of Al exposure; (2) the anemia
is preceded by microcytosis; (3) the anemia of uremia is enhanced by
Al.
Anémie microcytaire secondaire a l'aluminium intrapéritonéal chez
des rats normaux et uremiques. La dialyse de malades exposés a un di-
alysat contenant un aliminium élevé (Al) entraine une anémie micro-
cytaire reversible par dCsionisation (DI) du dialysat. Parce que DI
enlève en plus de I'Al des substances connues pour entrainer une
anémie, ces experiences ont été entreprises pour determiner si Al
entraine une anémie et si l'anémie de l'urémie peut étre majorée par
Al. Quatre groupes de rats ont été étudiés: des contrOles simulacres (A)N = 6; des contrOles uremiques (B) N = 6; des non uremiques
surchargés en Al (C) N = 7; et des uremiques surchargés en Al (D) N
= 5. Le traitement par l'aluminium comportait 1 mg Al par voie
intrapéntonéale chaque jour pendant 6 semaines. Les rats urémiques(B+D) étaient néphrectomisés aux 5/6 èmes; les non urémiques
(A + C) avaient subi un simulacre d'opération. Du sang (200 l) a été
obtenu avant (C1) et a chaque semaine de traItement (T1 a T6), et
analyse avec un Coulter Counter. Aucune difference significative dans
l'hemoglobine (Hb), l'hématocrite (Hct), ou le volume cellulaire moyen
(MCV) n'a été notée a C1. A T3, MCV de tous les rats traItés par l'Al
(C+D) était significativement moindre que chez les simulacres
contrôles (A)(55,1 0.5 et 53,0 0.8 contre 60,8 1,5 pt', P <0,05).
A T6, MCV, Hb, et Hct des rats urérniques surchargés en Al (D) (49
+ 0,5 s3; 11,8 0,5 g/dl); 25,1 2%) étaient significativement mom-
dres que chez A (58,6 1,3 s3; 16,1 0,4 g/dl; 44,8 0,3%) et B
(58,7 1,4 j: 13,8 0,4 g/dl; 33,6 + 0,5%) (P < 0,05) et MCV, Hb,
et Hct des rats non urémiques surchargés en Al (C) (51,7 1,7 3; 12,6
0.3 g/dl; 29,4 1.5%) étaient significativement plus faibles que chez
A (P < 0,05). Nous concluons que: (I) L'andmie est une manifestation
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toxique specifique de l'exposition a l'Al; (2) l'anémie est precédée
d'une microcytose; (3) l'anémie de l'urémie est majorée par l'Al.
Anemia is a major complication of chronic renal failure and
endstage renal disease. The pathogenesis of this anemia is com-
plex and multifactorial involving both decreased red cell (RBC)
production and shortened survival [1—3]. Recently, it has been
suggested that the first manifestation of aluminum (Al) toxicity
in this population may be worsening anemia [4, 5]. A profound
hypochromic microcytic anemia has been noted in patients
with dialysis dementia and vitamin D-resistant osteomalacia
[4—7], two disorders clearly linked to increased tissue burdens
of Al [4, 6, 8—10], and is also associated with high Al content
of the dialysate [5, 71. If the dialysate is changed from un-
treated water high in Al to deionized water, reversal of mor-
phological changes and an increase in hemoglobin (Hb) and
hematocrit (Hct) is noted [5, 71. Since multiple elements and
compounds capable of causing anemia are removed by deion-
ization [11], the evidence linking Al and anemia based on this
data must be considered circumstantial. We have attempted to
clarify this issue by investigating the changes in Hb, Hct, RBC
number, mean cell volume (MCV), mean cell Hb (MCH), and
mean cell Hb concentration (MCHC) as well as plasma and tis-
sue Al concentrations, reticulocytes, serum iron concentration
and fecal occult blood in aluminum-loaded normal and uremic
rats.
Methods
Four groups of male Sprague-Dawley rats (225 to 240 g) were
allowed free access to deionized distilled water and standard
diet (Wayne Lab Blox, Chicago, Illinois). After a 5-day accli-
mation, animals were lightly anesthetized with methoxyflurane
and approximately 200 rl blood obtained from the retroorbital
sinus for complete blood (CBC) and reticulocyte counts (C1 =
preoperative control period). The following day animals were
randomly assigned to either uremic or sham-operated groups
and anesthetized with intraperitoneal pentobarbital (50 mg/kg).
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Uremia was induced by two-stage 1 5/6 nephrectomy. Sham
animals were paired with uremic animals and two-stage sham-
operated animals. All rats were allowed 7 to 8 days to recover
between the two surgical procedures. Blood samples were ob-
tained weekly throughout the study by retroorbital puncture.
Following I week of recovery from surgery, blood was ob-
tained for CBC and blood urea nitrogen (BUN) (C2 = post-
operative control period) and animals further subdivided:
group A (N = 6) sham controls and group B (N = 6) uremic
controls received the intraperitoneal vehicle; group C (N — 7)
Al loaded non-uremic animals and group D (N = 5) Al-loaded
uremic animals received intraperitoneal Al. The Al solution
contained 1 mg/mI Al as aluminum chloride (AlCl3); the ve-
hicle was acidified 0.9% sodium chloride. The osmolarity and
pH of the vehicle and AId3 solutions were identical. Animals
were treated for 6 weeks and received 1 ml of vehicle or Al so-
lution daily intraperitoneally. The total dose of Al was 42 mg,
a dose previously shown to lead to bone Al levels comparable
to those seen in dialysis patients [12]. BUN was determined
prior to treatment (C2) and at week 6 of treatment (T6); a BUN
of greater than 40 mg/dl on both occasions was used as crite-
rion for uremia.
Stool for occult blood (Hemoccult II, Smith Klein Diagnos-
tics, Sunnyvale, California) was determined 1 week prior to
sacrifice. Animals were sacrificed by exsanguination via aortic
puncture and plasma obtained for BUN, iron, and Al determi-
nations. Bone and liver were obtained for Al analysis.
BUN was determined by standard kit (Sigma Chemical Co.,
St. Louis, Missouri) and serum iron by standard colorimetric
methods (Gemeni, Electro Nucleonics Inc., Fairlawn, New
Jersey). Tissue and plasma Al concentrations were determined
by flameless atomic absorption spectrophotometry (Varian Tech-
tron Model AA 1475, Varian Corp., Chicago, Illinois) as pre-
viously described [13]. Plasma Al was determined on diluted
samples. CBC was determined by Coulter Counter (MHR,
Model ZF) and reticulocyte counts by standard technique using
new methylene blue stain.
Hematological parameters as defined by Schalm, Jaen, and
Carroll [14] were used to define normal values for growing rats.
All data are expressed as the mean plus or minus SEM. Statis-
tical analysis of hematological parameters was by split plot
analysis of variance and least significant difference (LSD), with
P < 0.05 considered the criterion of statistical significance
(Tables 1 and 2, Figs. 2 and 3). Statistical comparisons were
made between groups (A, B, C, and D) at all time periods (C1
and C2, T2 to T6). Statistical comparisons were not made within
groups over time. Statistical analysis of other data (Tables 3
and 4) were by one-way analysis of variance and least signifi-
cant difference, with P < 0.05 considered the criterion of sta-
tistical significance.
Results
A comparison of hematological parameters was made be-
tween all groups at all time periods. As shown in Figure 1, Al-
loaded uremic rats (D) developed a significant microcytosis fol-
lowed by anemia. A similar but less profound pattern was
noted in Al-loaded non-uremic animals (C) (Table 1). At week
3 of treatment (T3) (Table 1) marked microcytosis was noted in
all Al-loaded rats (C and D) when compared to time controls
(A and B), and as microcytosis progressed, Hb and Hct (Fig.
3, Table 1) and red cell count (Table 2) declined. At the con-
clusion of the study (T6) MCV, Hb, and Hct of Al-loaded ure-
A
B
C
D
T1
13.7 0.2
13.3 0.3
13.0 0.5
13.5 0.5
15.2 0.2e
14.2 0.5
15.7 0.Y
13.8 0.lh
14.7 0.3
14.0 0.2
14.5 0.4
13.9 0.2
Hematocrit, %
A
B
C
D
T4
15.9 0.2
13.8 55b
14.5 0.3
13.8 0.4b
T5
15.6 + 0.1
13.7 0.5
13.8 0.6
13.0 0.5'
40.1 0.8
38.0 1.7
40.7 1.1
39.5 1.7k
T6
43.1 1.9c
43.3 8.8
44.1 3.9"
41.2 2.3
15.5 0.2
14.2 0.3
13.2 0.4
12.1 0.4h,c
44.1 5.7
36.7 2.5
39.1 2.1
38.1 1.4
16.2 0.2
14.6 0.3"
11.5 1.0
11.3 0.5'
44.1 3.8
37.3 1.9
41.0 3.5
39.2 1.6
16.1 0.4"
13.8 0.4"
12.6 0.3"
11.8 + 05"
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Table 1. Hemoglobin, hematocrit, and mean cell volume during the studya
Time, weeks
C, C2
Hemoglobin, gid!
Mean cell volume, /L3
A 62.4 0.51 60.5 0.3e 61.3 1.4 58.8 0.3 60.8 1.5 60.8 1.6 58.8 1.4 58.6 1.3"
B 61.5 0.3 69.0 4.0" 58.8 1.1 58.7 + 1.2 59.0 0.7 58.0 0.3 56.4 l.1 58.7 1.4
C 62.1 0.3 59.8 0.4 57.4 0.5 55.9 0.3 55.1 0.5k 54.1 1.3h 52.1 0.8" 51.7 l.75,c
D 63.2 0.7 64.8 3.4 57.6 0.8 56.2 1.4 53.0 0.8"' 52.8 + 1.3" 50.2 0.7" 49.0 0.5",'
Abbreviations: A, sham control, N = 6 except where indicated; B, uremic control, N = 6 except where indicated; C, Al-loaded non-uremic, N =
7 except where indicated; D, Al-loaded uremic, N = 5 except where indicated; C1, control samples taken 7 to 8 days prior to the first stage of sur-
gery; C2, control samples taken 7 days after the second stage of surgery; T, to T6, samples taken 1 through 6 weeks of treatment, respectively.
a Statistical analysis was by split-plot analysis of variance and least significant difference, with P < 0.05 considered the criterion of statistical
significance. All data are expressed as mean SEM. Comparisons were made between groups at all time periods. Comparisons were made between
control rats (A) and all other groups (B, C, and D) at all time periods (C1 and C2, and T, to T6) and between uremic control rats (B) and uremic Al-
loaded rats (D) at all time periods. Comparisons were not made within groups over time (see Methods).
b The value is significantly different from sham control (A) (P <0.05) at the time point indicated at the top of the table (C1 and C2, and T, to T6).
The value is significantly different from uremic control (B) (P < 0.05) at the time point indicated at the top of the table (C1 and C2, and T, to T6).
d N = 5; N = 4(3 values of 96, all in C2); 1N = 3(6 of 96 values, 4 in C1, one in C2 and one in C5).
44.5 2.3"
37.9 1.5
37.6 2.5
34.9 2.8"
46.1 4.8
39.4 5.1"
33.7 3•5b
30.3 1.2"'
44.5 8.3
37.2 2.0"
29.1 6.2"
27.0 2.5k
44.8 0.3"
33.6 0.5"
29.4 ÷ 1.5"
25.1 2.0""
Treatment time, weeks
Aluminum-induced microcytic anemia in the rat
Fig. 1. Time course in the development of microcytosis and anemia in
aluminum-treated uremic rats (group D). Results are expressed as
mean SEM. SEM less than 1 is not represented. Symbols are: hemo-
globin, 0; MCV, •. N equals 5 for all points, except during the con-
trol period, when N equals 3 for MCV only.
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Table 2. Red blood cell number (RBC), mean cell hemoglobin concentration (MCHC), and mean cell hemoglobin (MCH) postoperatively (C2),
and at 6 weeks of treatmenta
6
RCB x 106/liter MCHC, gidi MCH, pg
Group IVb C2 T6 C2 T6 C2 T6
A Sham control 7.2 0.1C 7.7 0.2 35.3 0.5" 35.9 0.7 21.3 0.5" 21.0 0.6
B Uremic control 6 6.3 O.2a 5.8 O.la 33.8 2.5" 44.0 3.2 22.8 O.7d 23.8 0.6
C Al-loaded nonuremic 7 7.4 0.4 5.7 O.2a 35.0 0.3 44.0 2.9 21.2 0.4 22.1 0.8
D Al-loaded uremic 5 6.1 0.la 5.1 0.4a 33.8 2.0 47.3 3.la 21.6 0.5 23.0 1.4
62
60
58
56
Abbreviations: C2, control samples taken 7 days after the second stage of surgery; T6, samples taken after 6 weeks of treatment.
a Statistical analysis by split-plot analysis of variance and least significant difference, with P < 0.05 considered the criterion of statistical
significance. Results are expressed as mean SEM. Statistical comparisons were made between groups (A vs. B, C, D, and B vs. D) at the two rep-
resentative time points indicated (C2 and T6). Comparisons were not made within groups (see Methods).
b N is as indicated above except in4icates N = 4, dindicates N = 5.
The value denotes a significant difference from control (A) at C2 or T6.
62
14
60
58
13 56
> 0 >U 0
E 54
C)I
12
52
50
11
'1
54
52
50
1
Pre 3 6
mic rats (D) were significantly less than sham (A) or uremic (B)
cpntrol rats; the red cell count was significantly less than sham
control (A).
Preoperative control CBC values (C1) were not significantly
different between groups (Tables I and 2). As expected post-
operative (C2) Hb, Hct, and the red cell count of uremic rats
(B and D) tended to be less than, and indices no different from,
non-uremic animals (A and C) (Tables 1 and 2). As anticipated
for growing rats [14], the Hb and Hct of non-uremic rats (A and
C) increased during the 16-day period between C1 and C2. Re-
ticulocyte counts, serum iron concentrations, and MCH were
not different. Fecal occult blood was detected in only one ure-
mic control animal. At both C2 and T6, the BUN of uremic ani-
Pre 3 6
Treatment time, weeks
Fig. 2. Mean cell volume (MCV) pretreatment and at 3 and 6 weeks of
treatment. Statistical analysis by split-plot analysis of variance and
LSD, with P < 0.05 considered the criterion of statistical significance.
Statistical comparisons were made between groups at representative
time points (C2, T3, and T6). Comparisons were not made within groups
(see Methods). Results are expressed as mean SENt. SEM less than 1
is not represented. Symbols are: sham control (A), •; uremic control
(B), A; Al-loaded non-uremic (C), 0; Al-loaded uremic (D), A; de-
notes significant difference from sham control (A) at the time-point in-
dicated, P < 0.05, denotes a significant difference from uremic con-
trol (B) at the time-point indicated, P < 0.05, 1. In group A N = 6,
except pretreatment and week 6, N = 5; in group B N = 6, except
pretreatment N = 3; in group C, N = 7, except pretreatment N = 3;
in group D, N = 5, except pretreatment N = 3.
mals (B and D) was significantly greater than non-uremic ani-
mals (A and C). There was no significant difference in BUN at
either C2 or T6 between uremic control (B) and Al-loaded ure-
mic (D) animals (Table 3). The T6 level of BUN correlates with
a decrement of renal function of approximately 60% [15].
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Table 3. BUN and weight prior to treatment and at sacrifice"
BUN, mg/dl Weight, g
C2 T6 C1 T6
Group N" Pretreatment Sacrifice Pretreatment Sacrifice
A
B
C
D
Sham control 6 25 1.0" 17 2.5 226 6
Uremic control 6 51 49f 72 11 .0" 238 9
Al-loaded non-uremic 7 25 0.9 23 2.6 236 6
Al-loaded uremic 5 62 1O.7 72 l1.6" 233 10
410 10
387 14
342 8"
311 2P
a Statistical analysis by one-way analysis of variance and LSD; results are expressed as mean SEM.
b N as indicated above except, c indicates N = 4; "indicates N = 5.
The value denotes a significant difference from sham control (A), P < 0.05 at the time specified.
The value denotes a significant difference from uremic control (B), P < 0.05 at the time specified.
Table 4. Plasma and tissue aluminum levels at sacrificea
Plasma Al Liver Al
Group N ppb ppm dry WI
Bone Al
ppm dry WI
A
B
C
D
Sham control 6 3.3 1.0 10.7 3.2
Uremic control 7 7.3 2.2 49.5 18.8
Al-loaded non-uremic 6 829.1 63.7c 370.3 27.9b,c
Al-loaded uremic 5 866.2 l0l.5"" 650.4 145.7""
23.1 5.3
19.6 3.7
181.6 33.7"
156.2 11.6""
a Statistical analysis by one-way analysis of variance and LSD; results are expressed as mean SEM.
The value denotes a significant difference from sham control (A) P < 0.05.
The value denotes a significant difference from uremic control (B) P < 0.05.
"N = 4.
Plasma, liver, and bone Al levels in Al-loaded animals (C and
D) were significantly greater than their respective non-Al-
loaded controls (A and B) (Table 4). No significant difference
in plasma, bone, or liver Al concentrations was seen between
sham control (A) and uremic control (B) nor between Al-loaded
non-uremic (C) and Al-loaded uremic animals (D).
All animals gained weight, but sham control rats (A) gained
more weight than did group B, C, and D rats (Table 3). From
week 4 through 6 of treatment (T4 to T6) sham (A) and uremic
control rats (B) weighed significantly more than Al-loaded ure-
mic animals (D). At week 6 of treatment (Tb) sham controls (A)
weighed significantly more than Al-loaded non-uremic animals
(C).
Discussion
This study demonstrates that microcytic anemia occurs after
intraperitoneal aluminum loading in both normal and uremic
rats and that the anemia is preceded by significant micro-
cytosis. The absence of reticulocytosis and the occurrence of
microcytosis followed by a decrease in Hb and Hct, a pattern
which mimics the iron (Fe) deficiency and lead (Pb) intoxica-
tion anemias of humans, suggests the mechanism of Al-in-
duced anemia involves decreased red cell production.
The human anemia of lead intoxication is characterized by
interference with heme synthesis [16, 17]. Activity of red blood
cell (RBC) delta aminolevulinic acid dehydratase (ALAD), the
second and rate-limiting enzyme in heme biosynthesis, is now
widely accepted as an accurate measure of human environmen-
tal lead exposure [16—19]. Since Al has been shown to alter the
activity of a number of enzyme systems [20—23], it seems pos-
sible that Al may also interfere with enzymes involved in heme
biosynthesis. Although the effect of Al on ALAD activity has
been examined, the results are inconsistent and greatly depend
on the experimental conditions, the concentration of Al, and
the presence or absence of other metal ions [16, 24, 25]. Mer-
edith et al [16] have found a significant decrease in RBC ALAD
activity in hemodialysis patients, but were unable to correlate
this decreased ALAD activity with elevated Al levels. Further-
more the effects of zinc (Zn), Pb, and Al could not be sepa-
rated. Abdulla, Svensson, and Haeger-Aronson [25] demon-
strated an inhibitory effect of Al on ALAD activity at all con-
centrations in vitro, while similar concentrations of Al activated
the enzyme in vivo. In vitro studies by Meredith, Moore, and
Goldbert [24] showed enhanced ALAD activity with 2 mM Al,
but inhibition of ALAD activity with 4 mM Al. Zinc and Al ac-
tivate ALAD in vivo, but increasing Al concentrations inhibit
Zn-mediated activation of ALAD in vitro [251. Aluminum and
Pb additively inhibit ALAD activity but the addition of Zn
leads to reactivation of ALAD [251. Thus, the specific effects
of Al on ALAD activity in dialysis patients are complex and
await clarification. However, it is clear that aluminum, acting
alone or in concert with other metals, could impair the synthe-
sis of heme by altering ALAD or other enzyme activity.
Our uremic rats (B) demonstrated a lower Hb and Hct at all
treatment periods when compared to the time control normal
rats (A). Although not as severe as the anemia seen n dialysis
patients, uremic rats developed anemia with a decrement in re-
nal function of approximately 60% [15]; a decrease in renal
function which is also less than that seen in dialysis patients.
A general correlation between the degree of uremia and the se-
verity of anemia has been noted [261 and a BUN of greater than
100 mg/dl is almost always associated with a Hct of less than
30% [261. In addition, this study was performed on growing
rats, in which a time-dependent increase in Hb and Hct is ex-
pected [141. Although the Hb and Hct of uremic rats may ap-
pear not to change over time, failure of these values to in-
Treatment time, weeks
Fig. 3. Hemoglobin pretreatment and at 3 and 6 weeks of treatment.
Statistical analysis by split-plot analysis of variance and least signifi-
cant difference, with P < 0.05 considered the criterion of statistical sig-
nificance. Statistical comparisons were made between groups at rep-
resentative time points (C2, T3, and T6). Comparisons were not made
within groups (see Results). Results are expressed as mean SCM. SEM
less than 1 is not represented. Symbols are: sham control (A), •; ure-
mic control (B), A; Al-loaded non-uremic (C), 0; Al-loaded uremic
(D), A; denotes a significant difference from sham control (A) at the
time-point indicated, P < 0.05, *; denotes significant difference from
uremic control (B) at the time-point indicated, P < 0.05, 1. In group A
N = 6, except week 6, N = 5; in group B, N = 6; in group C, N = 7;
and in group D, N = 5.
mic patients, it is likely that the mechanism of this anemia is
similar in rats and humans, and that further investigation using
this rat model will uncover the pathophysiologic events by
which aluminum produces anemia.
Acknowledgments
These data were presented in part at the 15th Annual Meeting of the
American Society of Nephrology, Chicago, Illinois, and were sup-
ported in part by Biomedical Research Support Grant S07 RR05772-08.
The authors thank the staff of the Clinical Center Laboratory, J.
Kovan, and T. Doyle for technical assistance and Drs. G. Fink and B.
Bull for advice and support.
Reprint requests to Dr. L. Kaiser, Department of Physiology, Michi-
gan State University, East Lansing, Michigan 48824, USA
References
1. CAR0 J, BROWN S, MILLER 0, MURRAY T, ERSLEY AJ:
Erythropoietin levels in uremic nephric and anephric patients. J
Lab C/in Med 93:449—458, 1979
2. LINKESCH W, STUMMv0LL HK, WOLF A, MULLER M: Heme syn-
thesis in anemia of the uremia state. Is J Med Sd 14:1173—1176,
1978
3. SWAMY AP, KOTHARI T, LEE JCK, CESTERO RVM, MANGLA JC:
Iron supplements and hemosiderosis in chronic renal failure. Dial-
ysis Transplant 9: 1073—1 121, 1980
4. ELLIOTT HL, DRYBURGH F, FELL GS, SABET S, MACDOUGALL
AT: Aluminum toxicity during regular haemodialysis. Br Med J
1:1101—1103, 1978
5. SHORT AIK, WINNEY Ri, ROBSON JS: Reversible microcytic hypo-
chromic anaemia in dialysis patients due to aluminum intoxica-
tion. Proc Eur Dial Transplant Assoc 17:233—236, 1980
6. PARKINSON IS, WARD MK, KERR DNS: Dialysis encephalopathy,
bone disease and anaemia: The aluminum intoxication syndrome
during regular haemodialysis. J C/in Pathol 34:1285—1294, 1981
7. O'HARE AT, MURNAGHAN DJ: Reversal of aluminum-induced he-
modialysis anemia by low-aluminum dialysate. N EngI J Med
306:654—656, 1982
8. ALFREY AC, LEGENDRE OR, KAEHNY WD: The dialysis enceph-
alopathy syndrome: Possible aluminum intoxication. N EngI J Med
294:184—l88, 1976
9. ELLIOTT HL, MACDOUGALL Al, FELL GS, GARDINER PHE, WIL-
LIAMS ED: Dialysis encephalopathy — Evidence implicating alu-
minum. Dialysis Transplant 9:1029—1030, 1980
10. MCDERMOTT JR, SMITH Al, WARD MK, PARKINSON IS, KERR
DNS: Brain aluminum concentration in dialysis encephalopathy.
Lancet 1:901—904, 1978
11. WILLS MR, SAVORY J: Aluminum poisoning: Dialysis encepha-
lopathy, osteomalacia, and anemia. Lancet 2:29—33, 1983
12. ELLIS HA, MCCARTHY JH, HERRINGTON J: Bone aluminum in
haemodialysis patients and in rats injected with aluminum chlo-
ride: Relationship to impaired bone mineralization. J C/in Pathol
32:832—844, 1979
13. MCCORMACK KM, OTTOSEN LD, SANGER VL, SPRAGUE S,
MAYOR GH, HOOK JB: Effect of prenatal administration of alumi-
num and parathyroid hormone on fetal development of the rat.
Proc Soc Exp Biol Med 16 1:74-77, 1979
14. SCHALM OW, JAEN NC, CARROLL EJ: Veterinary Hematology
(3rd ed). Philadelphia, Pennsylvania, 1975, pp 235—246
15. KAUFMAN JM, DIMEOLA HJ, SIEGEL NJ, LYTTON B, KASHGAR-
IAN M, HAYSLETT JP: Compensatory adaptation of structure and
function following progressive renal ablation. Kidney mt 6:10—17,
1974
16. MEREDITH PA, ELLIOTT HL, CAMPBELL BC, MOORE MR:
Changes in serum aluminum blood zinc, blood lead and erythro-
cyte b-aminolaevulinic acid dehydratase activity during haemodi-
alysis. Toxicol Letters 4:419—424, 1979
17. GARNICA AD: Trace metals and hemoglobin metabolism. Ann Clin
Lab Sci 11:220—228, 1981
Aluminum-induced microcytic anemia in the rat 273
16
14
12
10
05
C
0
050
E
a)I
Pre 3 6
crease to levels comparable to their time controls indicates that
despite only a 60% decrease in renal function, our uremic rats
were anemic. The modest uremia and anemia in our uremic
model permitted us to demonstrate exacerbation of anemia
with aluminum.
The MCH of all groups was not significantly different at any
time period during the study. Human studies of presumed Al-
induced anemia demonstrated a slight but significant decrease
in MCH [171. However, in the absence of reticulocytosis, a mi-
crocytic anemia with or without a decrease in MGH, points to
an alteration of red cell production. Although the mechanism
of Al-induced microcytosis and anemia appears to involve the
synthesis of heme, the exact mechanism awaits elucidation.
Our animals showed no evidence of blood loss, iron defi-
ciency, or hemolysis. Although Al-loaded animals failed to gain
as much weight as control rats, significant microcytosis oc-
cuffed prior to a significant difference in weight, making it un-
likely that nutritional factors were involved in the anemia seen
in these animals.
In summary, aluminum loading results in a microcytic ane-
mia in rats. Since our rat model faithfully reproduces the clin-
ical picture of presumed aluminum-induced anemia seen in ure-
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